SEC Form 4 · accession 0001209191-16-134106
MERRIMACK PHARMACEUTICALS INC · MACK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Birgit M. Schoeberl
Officer — Head of Discovery
Period of report
Jul 25, 2016
Accepted (ET)
Jul 27, 2016 · 4:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001274792
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 25, 2016 | M | 50,000 | $2.12 | A | 115,657 | D | |
| Common StockF2 | Jul 25, 2016 | S | 50,000 | $5.50 | D | 65,657 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $2.12 | Jul 25, 2016 | M | 50,000 | D | — | Aug 1, 2016 | Common Stock | 50,000 | 0 | D |
Explanation of responses
- F1This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.39 to $5.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F3This option is fully vested.